Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) Net Margin (2016 - 2025)

Amicus Therapeutics (FOLD) has disclosed Net Margin for 16 consecutive years, with 0.91% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Margin fell 893.0% year-over-year to 0.91%, compared with a TTM value of 4.27% through Dec 2025, up 635.0%, and an annual FY2025 reading of 4.27%, up 635.0% over the prior year.
  • Net Margin was 0.91% for Q4 2025 at Amicus Therapeutics, down from 10.24% in the prior quarter.
  • Across five years, Net Margin topped out at 10.24% in Q3 2025 and bottomed at 108.31% in Q1 2022.
  • Average Net Margin over 5 years is 42.48%, with a median of 42.3% recorded in 2022.
  • The sharpest move saw Net Margin skyrocketed 4807bps in 2021, then crashed -1082bps in 2022.
  • Year by year, Net Margin stood at 101.37% in 2021, then surged by 37bps to 63.41% in 2022, then soared by 54bps to 29.41% in 2023, then surged by 133bps to 9.85% in 2024, then crashed by -91bps to 0.91% in 2025.
  • Business Quant data shows Net Margin for FOLD at 0.91% in Q4 2025, 10.24% in Q3 2025, and 15.79% in Q2 2025.